Martin Runnstrom
Research Subjects
Research Interests
Martin Runnstrom has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adonice PharmD Khoury
Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Gainesville, USA
2 shared publications - Alex M. Ebied
Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, NC
2 shared publications Andrea Morrison-Porter
Department of Pathology and Laboratory Medicine, Emory University School of Medicine
1 shared publicationAndrew S. Neish
Department of Pathology and Laboratory Medicine, Emory University School of Medicine
1 shared publication- Arezou Khosroshahi
Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA
1 shared publication - Caterina E. Faliti
Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
Novel mRNA vaccines have resulted in a reduced number of SARS-CoV-2 infections and hospitalizations. Yet, there is a paucity of studies regarding their effectiveness on immunocompromised autoimmune subjects. In this study, we enrolled subjects naïve to SARS-CoV-2 infections from two cohorts of healthy donors (HD, n=56) and systemic lupus erythematosus (SLE, n=69). Serological assessments of their circulating antibodies revealed a significant reduction of potency and breadth of neutralization in the SLE group, only partially rescued by a 3 rd booster dose. Immunological memory responses in the SLE cohort were characterized by a reduced magnitude of spike-reactive B and T cell responses that were strongly associated with poor seroconversion. Vaccinated SLE subjects were defined by a distinct expansion and persistence of a DN2 spike-reactive memory B cell pool and a contraction of spike-specific memory cTfh cells, contrasting with the sustained germinal center (GC)-driven activity mediated by mRNA vaccination in the healthy population. Among the SLE-associated factors that dampened the vaccine responses, treatment with the monoclonal antibody anti-BAFF/Belimumab (a lupus FDA-approved B cell targeting agent) profoundly affected the vaccine responsiveness by restricting the de novo B cell responses and promoting stronger extra-follicular (EF)-mediated responses that were associated with poor immunogenicity and impaired immunological memory. In summary, this study interrogates antigen-specific responses and characterized the immune cell landscape associated with mRNA vaccination in SLE. The identification of factors associated with reduced vaccine efficacy illustrates the impact of SLE B cell biology on mRNA vaccine responses and provides guidance for the management of boosters and recall vaccinations in SLE patients according to their disease endotype and modality of treatment.
Open AccessPoor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
Novel mRNA vaccines have resulted in a reduced number of SARS-CoV-2 infections and hospitalizations. Yet, there is a paucity of studies regarding their effectiveness on immunocompromised autoimmune subjects. In this study, we enrolled subjects naïve to SARS-CoV-2 infections from two cohorts of healthy donors (HD, n=56) and systemic lupus erythematosus (SLE, n=69). Serological assessments of their circulating antibodies revealed a significant reduction of potency and breadth of neutralization in the SLE group, only partially rescued by a 3 rd booster dose. Immunological memory responses in the SLE cohort were characterized by a reduced magnitude of spike-reactive B and T cell responses that were strongly associated with poor seroconversion. Vaccinated SLE subjects were defined by a distinct expansion and persistence of a DN2 spike-reactive memory B cell pool and a contraction of spike-specific memory cTfh cells, contrasting with the sustained germinal center (GC)-driven activity mediated by mRNA vaccination in the healthy population. Among the SLE-associated factors that dampened the vaccine responses, treatment with the monoclonal antibody anti-BAFF/Belimumab (a lupus FDA-approved B cell targeting agent) profoundly affected the vaccine responsiveness by restricting the de novo B cell responses and promoting stronger extra-follicular (EF)-mediated responses that were associated with poor immunogenicity and impaired immunological memory. In summary, this study interrogates antigen-specific responses and characterized the immune cell landscape associated with mRNA vaccination in SLE. The identification of factors associated with reduced vaccine efficacy illustrates the impact of SLE B cell biology on mRNA vaccine responses and provides guidance for the management of boosters and recall vaccinations in SLE patients according to their disease endotype and modality of treatment.
- 1 December 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (11) , 1576-1578
Wiping Out Wheezing: Novel Therapeutic Targets for Patients with Severe Asthma
In 2003, the first biologic therapy (omalizumab) for asthma was U.S. Food and Drug Administration approved and immediately revolutionized the treatment of patients with severe asthma, including patients with evidence of type 2 (T2) inflammation. In the years since approval, additional monoclonal antibodies against T2-high asthma targets have widened the therapeutic landscape and include antagonists to IL-5 (mepolizumab and reslizumab), the IL-5 receptor (benralizumab), and the IL-4 receptor (dupilumab). These medications have shown considerable efficacy, yet some patients with severe asthma have no initial response, cannot tolerate the adverse reactions, or lose therapeutic response with time. Although there are many medications in development to improve asthma management, the following articles outline three new promising and not-so-promising approaches for the treatment of severe T2-high asthma.
- 1 December 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (11) , 1576-1578
Wiping Out Wheezing: Novel Therapeutic Targets for Patients with Severe Asthma
In 2003, the first biologic therapy (omalizumab) for asthma was U.S. Food and Drug Administration approved and immediately revolutionized the treatment of patients with severe asthma, including patients with evidence of type 2 (T2) inflammation. In the years since approval, additional monoclonal antibodies against T2-high asthma targets have widened the therapeutic landscape and include antagonists to IL-5 (mepolizumab and reslizumab), the IL-5 receptor (benralizumab), and the IL-4 receptor (dupilumab). These medications have shown considerable efficacy, yet some patients with severe asthma have no initial response, cannot tolerate the adverse reactions, or lose therapeutic response with time. Although there are many medications in development to improve asthma management, the following articles outline three new promising and not-so-promising approaches for the treatment of severe T2-high asthma.
- Open Access
- 1 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 11 (1) , e226610
Influenza-induced rhabdomyolysis
Rhabdomyolysis is characterised by muscle breakdown with release of damaging proteins that can have devastating consequences. Acute influenza infection is being increasingly recognised as an underlying aetiology. We report an unusual case of severe rhabdomyolysis with acute renal failure due to influenza A infection that improved with high-dose oseltamivir and intravenous fluids. In our case, we also noticed a temporal relation between fever spikes and subsequent increase in serum creatine kinase. The precise mechanism between the rise in temperature and creatine kinase is unclear but it could be due to direct viral invasion of myocytes or due to release of new viral progeny following replication in the myocyte.
- 1 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 11 (1) , e226610
Open AccessInfluenza-induced rhabdomyolysis
Rhabdomyolysis is characterised by muscle breakdown with release of damaging proteins that can have devastating consequences. Acute influenza infection is being increasingly recognised as an underlying aetiology. We report an unusual case of severe rhabdomyolysis with acute renal failure due to influenza A infection that improved with high-dose oseltamivir and intravenous fluids. In our case, we also noticed a temporal relation between fever spikes and subsequent increase in serum creatine kinase. The precise mechanism between the rise in temperature and creatine kinase is unclear but it could be due to direct viral invasion of myocytes or due to release of new viral progeny following replication in the myocyte.
- 30 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations
We report a case of a hospitalised patient who developed probable serotonin toxicity shortly after the initiation of linezolid in whom the selective serotonin reuptake inhibitor (SSRI) escitalopram had been recently discontinued. On day 2 of linezolid administration, the patient reported severe anxiety and was observed to have full body jerking and twitching motions without mental status change. Notably, the patient was concomitantly receiving the antidepressant, trazodone and the benzodiazepine, clonazepam possibly affecting the severity and manifestations of serotonin toxicity. Linezolid was discontinued after 5 days and the patient’s symptoms resolved. Serotonin toxicity can present with an array of symptoms and be life threatening if left unrecognised. This report highlights the clinical lessons that discontinuation of an SSRI upon initiation of linezolid does not eliminate the risk of serotonin toxicity and that other concomitant medications may worsen or improve some of the symptoms lending delay and uncertainty to the diagnosis.
- 30 October 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations
We report a case of a hospitalised patient who developed probable serotonin toxicity shortly after the initiation of linezolid in whom the selective serotonin reuptake inhibitor (SSRI) escitalopram had been recently discontinued. On day 2 of linezolid administration, the patient reported severe anxiety and was observed to have full body jerking and twitching motions without mental status change. Notably, the patient was concomitantly receiving the antidepressant, trazodone and the benzodiazepine, clonazepam possibly affecting the severity and manifestations of serotonin toxicity. Linezolid was discontinued after 5 days and the patient’s symptoms resolved. Serotonin toxicity can present with an array of symptoms and be life threatening if left unrecognised. This report highlights the clinical lessons that discontinuation of an SSRI upon initiation of linezolid does not eliminate the risk of serotonin toxicity and that other concomitant medications may worsen or improve some of the symptoms lending delay and uncertainty to the diagnosis.
- Open Access
Pasteurella multocida prosthetic joint infection